Rubicon Technology Inc (NASDAQ:RBCN)’s share price fell 13.3% on Friday following a dissappointing earnings announcement,American Banking and Market News reports. The company traded as low as $8.59 and last traded at $8.83, with a volume of 1,446,420 shares. Rubicon Technology, Inc. (NASDAQ:RBCN) shares after opening at $9.10 moved to $9.31 on last trade day and at the end of the day closed at $8.51 . Company price to sales ratio in past twelve months was calculated as 4.69 and price to cash ratio as 3.52. Rubicon Technology, Inc. (NASDAQ:RBCN) showed a negative weekly performance of -17.06%.
Sierra Wireless Inc. (USA) (NASDAQ:SWIR) posted its quarterly earnings results on Thursday. The company reported $0.02 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.03 by $0.01,American Banking and Market News reports. The company had revenue of $121.20 million for the quarter, compared to the consensus estimate of $119.18 million. During the same quarter last year, the company posted ($0.02) earnings per share. Sierra Wireless’s revenue was up 19.5% compared to the same quarter last year. Sierra Wireless updated its Q2 guidance to $0.06-$0.08 EPS. Sierra Wireless, Inc. (USA) (NASDAQ:SWIR) shares fell -12.86% in last trading session and ended the day on $19.25. SWIR return on equity ratio is recorded as 16.20% and its return on assets is 11.20%. Sierra Wireless, Inc. (USA) (NASDAQ:SWIR) yearly performance is 78.57%.
Blucora Inc (NASDAQ:BCOR) was downgraded by analysts at Craig Hallum from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, TheFlyOnTheWall.com reports. Blucora Inc (NASDAQ:BCOR) shares moved down -9.88% in last trading session and was closed at $17.51 while trading in range of $16.65 – $17.77 – Blucora Inc (NASDAQ:BCOR) year to date (YTD) performance is -39.95%.
Seattle Genetics, Inc. (NASDAQ:SGEN) reported financial results for the first quarter ended March 31, 2014. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development accomplishments, progress with its antibody-drug conjugate (ADC) pipeline, collaborator updates and upcoming activities. Seattle Genetics, Inc. (NASDAQ:SGEN) weekly performance is -7.88%. On last trading day company shares ended up $34.50. Seattle Genetics, Inc. (NASDAQ:SGEN) distance from 50-day simple moving average (SMA50) is -25.28%. Analysts mean target price for the company is $45.62.